Effect of interferon-α on chromosome abnormalities in treated chronic myelogenous leukemia patients

Tanaka, Hideo; Tanaka, Kimio; Oguma, Nobuo; Ito, Kinro; Ito, Takuo; Kyo, Taiichi; Dohy, Hiroo; Kimura, Akiro

doi:10.1016/j.cancergencyto.2004.01.019

Cited by 7 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As in past studies, trisomy 8 was the most common cytogenetic abnormality observed in Ph− cells of CML patients treated with imatinib (Tanaka et al. , 2004; Terre et al.…”

Section: Discussionsupporting

confidence: 58%

“…Several hypotheses were set forth with respect to the emergence of secondary genetic abnormalities in Ph− cells during imatinib therapy. One hypothesis suggests that these secondary genetic abnormalities are induced by the innate genetic instability of CML cells, rather than being a treatment‐related active phenomenon (Tanaka et al. , 2004).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Transient trisomy 8 abnormality in Philadelphia‐negative cells during imatinib mesylate treatment of chronic myelogenous leukemia

Kim

Lee

Jung

et al. 2008

Int J Lab Hematology

View full text Add to dashboard Cite

We investigated chronic myelogenous leukemia (CML) patients who developed trisomy 8 abnormalities in Philadelphia-negative (Ph-) cells during imatinib mesylate treatment to evaluate the clinical outcome and laboratory features. Of the 470 CML patients, 1.5% (n = 7) developed trisomy 8 chromosomal abnormalities in Ph- cells. The median interval of the first trisomy 8 observation was 12 months. Our follow-up cytogenetic evaluations revealed that six of the patients demonstrated a complete or partial cytogenetic response and that all of the six patients revealed no dysplastic changes following a bone marrow examination. Moreover, the percentage of trisomy 8 in metaphase karyotyping has decreased in five of the seven subjects. In conclusion, these results suggest that the emergence of trisomy 8 in Ph- cells is transient and not related to therapy-related myelodysplasia or acute leukemia.

show abstract

“…As in past studies, trisomy 8 was the most common cytogenetic abnormality observed in Ph− cells of CML patients treated with imatinib (Tanaka et al. , 2004; Terre et al.…”

Section: Discussionsupporting

confidence: 58%

Section: Discussionmentioning

confidence: 99%

Transient trisomy 8 abnormality in Philadelphia‐negative cells during imatinib mesylate treatment of chronic myelogenous leukemia

Kim

Lee

Jung

et al. 2008

Int J Lab Hematology

View full text Add to dashboard Cite

show abstract

“…The third hypothesis stresses that the innate genetic instability of CML marrow may cause the development of chromosomal evolution (Tanaka et al, 2004). Since the fact that most of our cases continued on imatinib therapy during the occurrence of Phnegative abnormality and many of the abnormalities disappeared on imatinib therapy, as shown in other reports, our data, at least, did not favor the theory that imatinib alone could contribute to the abnormalities.…”

Section: Discussionmentioning

confidence: 43%

Philadelphia-negative chromosomal evolution during treatment for chronic myeloid leukemia

Hsiao

Liu²,

Lee³

et al. 2012

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Chromosome evolution is one of the major mechanisms of disease progression and resistance in chronic myeloid leukemia (CML) patients. However, the clinical significance of chromosomal evolution in the Philadelphia (Ph)-negative clone during therapy is not fully understood. We evaluated 94 CML patients in the chronic phase of CML during treatment of the disease. Six of them had Ph-negative chromosome abnormalities during treatment. Four patients with a single abnormality and a good molecular response showed no obvious complications from the chromosomal changes, while two other patients who had complex abnormalities and previous treatment had poor outcomes. Our results highlight the need for close monitoring of this kind of patient, not only on a molecular level but also at the cytogenetic level.

show abstract

“…The third hypothesis stresses that the innate genetic instability of CML marrow may cause the development of chromosomal evolution (Tanaka et al, 2004). Since the fact that most of cases continued on TKI therapy during the occurrence of Ph-negative abnormality and many of the abnormalities disappeared on TKI therapy, as shown in many reports, our data, did not favor the theory that TKI alone could contribute to the abnormalities (Bennour et al, 2015).…”

Section: Additional Chromosomal Abnormalities In Ph-negative CMLmentioning

confidence: 57%

“…The reproducible results depend on the use of good quality commercial probes with a low false positive rate that brings the sensitivity of FISH assays to 1-6% (Tanaka et al, 2004).…”

Section: Fishmentioning

confidence: 99%

Chronic myeloid leukemia: Relevance of cytogenetic and molecular assays

Bennour

Sarkhosh

Sennana

2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Effect of interferon-α on chromosome abnormalities in treated chronic myelogenous leukemia patients

Cited by 7 publications

References 32 publications

Transient trisomy 8 abnormality in Philadelphia‐negative cells during imatinib mesylate treatment of chronic myelogenous leukemia

Transient trisomy 8 abnormality in Philadelphia‐negative cells during imatinib mesylate treatment of chronic myelogenous leukemia

Philadelphia-negative chromosomal evolution during treatment for chronic myeloid leukemia

Chronic myeloid leukemia: Relevance of cytogenetic and molecular assays

Contact Info

Product

Resources

About